Clinical trial
A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to…
NCT00074984 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00074984 |
|---|---|
| Title | A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease |
| Official title | Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Fabrazyme on Progression of Renal Disease and Significant Clinical Events in Patients With Fabry Disease |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Fabry Disease |
| Intervention type | Biological |
| Interventions | Fabrazyme (agalsidase beta), Placebo |
| Enrollment | 82 |
| Start date | Feb 1, 2001 |
| Primary completion | Jan 1, 2004 |
| Completion | Jan 1, 2004 |
| First posted | Dec 25, 2003 |
| Last update posted | Dec 27, 2013 |
| Countries | Canada, Czechia, Hungary, Poland, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: